These findings suggest that cardiovascular benefits of GLP-1 RAs may be modified by BMI, while kidney benefits were consistent regardless of BMI, supporting individualized treatment decisions in type 2 diabetes care. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.